These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

863 related articles for article (PubMed ID: 15824152)

  • 1. Frequent methylation of eyes absent 4 gene in Barrett's esophagus and esophageal adenocarcinoma.
    Zou H; Osborn NK; Harrington JJ; Klatt KK; Molina JR; Burgart LJ; Ahlquist DA
    Cancer Epidemiol Biomarkers Prev; 2005 Apr; 14(4):830-4. PubMed ID: 15824152
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Aberrant methylation of secreted frizzled-related protein genes in esophageal adenocarcinoma and Barrett's esophagus.
    Zou H; Molina JR; Harrington JJ; Osborn NK; Klatt KK; Romero Y; Burgart LJ; Ahlquist DA
    Int J Cancer; 2005 Sep; 116(4):584-91. PubMed ID: 15825175
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Progression of Barrett's metaplasia to adenocarcinoma is associated with the suppression of the transcriptional programs of epidermal differentiation.
    Kimchi ET; Posner MC; Park JO; Darga TE; Kocherginsky M; Karrison T; Hart J; Smith KD; Mezhir JJ; Weichselbaum RR; Khodarev NN
    Cancer Res; 2005 Apr; 65(8):3146-54. PubMed ID: 15833844
    [TBL] [Abstract][Full Text] [Related]  

  • 4. p16 expression in Barrett's esophagus and esophageal adenocarcinoma: association with genetic and epigenetic alterations.
    Hardie LJ; Darnton SJ; Wallis YL; Chauhan A; Hainaut P; Wild CP; Casson AG
    Cancer Lett; 2005 Jan; 217(2):221-30. PubMed ID: 15617840
    [TBL] [Abstract][Full Text] [Related]  

  • 5. p53 gene mutation and protein accumulation during neoplastic progression in Barrett's esophagus.
    Bian YS; Osterheld MC; Bosman FT; Benhattar J; Fontolliet C
    Mod Pathol; 2001 May; 14(5):397-403. PubMed ID: 11353048
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A multigene expression panel for the molecular diagnosis of Barrett's esophagus and Barrett's adenocarcinoma of the esophagus.
    Brabender J; Marjoram P; Salonga D; Metzger R; Schneider PM; Park JM; Schneider S; Hölscher AH; Yin J; Meltzer SJ; Danenberg KD; Danenberg PV; Lord RV
    Oncogene; 2004 Jun; 23(27):4780-8. PubMed ID: 15107828
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expression of beta-catenin, alpha-catenin, and E-cadherin in Barrett's esophagus and esophageal adenocarcinomas.
    Washington K; Chiappori A; Hamilton K; Shyr Y; Blanke C; Johnson D; Sawyers J; Beauchamp D
    Mod Pathol; 1998 Sep; 11(9):805-13. PubMed ID: 9758359
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Increased c-myb mRNA expression in Barrett's esophagus and Barrett's-associated adenocarcinoma.
    Brabender J; Lord RV; Danenberg KD; Metzger R; Schneider PM; Park JM; Salonga D; Groshen S; Tsao-Wei DD; DeMeester TR; Hölscher AH; Danenberg PV
    J Surg Res; 2001 Aug; 99(2):301-6. PubMed ID: 11469901
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The molecular signature of normal squamous esophageal epithelium identifies the presence of a field effect and can discriminate between patients with Barrett's esophagus and patients with Barrett's-associated adenocarcinoma.
    Brabender J; Marjoram P; Lord RV; Metzger R; Salonga D; Vallböhmer D; Schäfer H; Danenberg KD; Danenberg PV; Selaru FM; Baldus SE; Hölscher AH; Meltzer SJ; Schneider PM
    Cancer Epidemiol Biomarkers Prev; 2005 Sep; 14(9):2113-7. PubMed ID: 16172218
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expression of the bile acid receptor FXR in Barrett's esophagus and enhancement of apoptosis by guggulsterone in vitro.
    De Gottardi A; Dumonceau JM; Bruttin F; Vonlaufen A; Morard I; Spahr L; Rubbia-Brandt L; Frossard JL; Dinjens WN; Rabinovitch PS; Hadengue A
    Mol Cancer; 2006 Oct; 5():48. PubMed ID: 17054793
    [TBL] [Abstract][Full Text] [Related]  

  • 11. P53 mutational status improves estimation of prognosis in patients with curatively resected adenocarcinoma in Barrett's esophagus.
    Schneider PM; Stoeltzing O; Roth JA; Hoelscher AH; Wegerer S; Mizumoto S; Becker K; Dittler HJ; Fink U; Siewert JR
    Clin Cancer Res; 2000 Aug; 6(8):3153-8. PubMed ID: 10955797
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Abundant expression of the intestinal protein villin in Barrett's metaplasia and esophageal adenocarcinomas.
    Regalado SP; Nambu Y; Iannettoni MD; Orringer MB; Beer DG
    Mol Carcinog; 1998 Jul; 22(3):182-9. PubMed ID: 9688144
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Proinflammatory cytokine and nuclear factor kappa-B expression along the inflammation-metaplasia-dysplasia-adenocarcinoma sequence in the esophagus.
    O'Riordan JM; Abdel-latif MM; Ravi N; McNamara D; Byrne PJ; McDonald GS; Keeling PW; Kelleher D; Reynolds JV
    Am J Gastroenterol; 2005 Jun; 100(6):1257-64. PubMed ID: 15929754
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dedifferentiation precedes invasion in the progression from Barrett's metaplasia to esophageal adenocarcinoma.
    Helm J; Enkemann SA; Coppola D; Barthel JS; Kelley ST; Yeatman TJ
    Clin Cancer Res; 2005 Apr; 11(7):2478-85. PubMed ID: 15814623
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Polymorphism/loss of heterozygosity of APC gene in GERD-Barrett's metaplasia-dysplasia-adenocarcinoma sequence].
    Mokrowiecka A; Wierzchniewska-Ławska A; Smolarz B; Romanowicz-Makowska H; Malecka-Panas E
    Pol Merkur Lekarski; 2009 May; 26(155):385-9. PubMed ID: 19606680
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Methylation of APC, TIMP3, and TERT: a new predictive marker to distinguish Barrett's oesophagus patients at risk for malignant transformation.
    Clément G; Braunschweig R; Pasquier N; Bosman FT; Benhattar J
    J Pathol; 2006 Jan; 208(1):100-7. PubMed ID: 16278815
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hypermethylation of the AKAP12 promoter is a biomarker of Barrett's-associated esophageal neoplastic progression.
    Jin Z; Hamilton JP; Yang J; Mori Y; Olaru A; Sato F; Ito T; Kan T; Cheng Y; Paun B; David S; Beer DG; Agarwal R; Abraham JM; Meltzer SJ
    Cancer Epidemiol Biomarkers Prev; 2008 Jan; 17(1):111-7. PubMed ID: 18199717
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mucin expression and proliferating cell index of esophageal Barrett's adenocarcinoma.
    Yamamoto S; Kijima H; Hara T; Chino O; Shimada H; Tanaka M; Inokuchi S; Makuuchi H
    Int J Mol Med; 2005 Sep; 16(3):375-80. PubMed ID: 16077942
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Survivin, a potential biomarker in the development of Barrett's adenocarcinoma.
    Vallböhmer D; Peters JH; Oh D; Kuramochi H; Shimizu D; Demeester SR; Hagen JA; Chandrasoma PT; Danenberg KD; DeMeester TR; Danenberg P
    Surgery; 2005 Oct; 138(4):701-6; discussion 706-7. PubMed ID: 16269299
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Transforming growth factor-alpha, epidermal growth factor receptor, and MiB-1 expression in Barrett's-associated neoplasia: correlation with prognosis.
    Yacoub L; Goldman H; Odze RD
    Mod Pathol; 1997 Feb; 10(2):105-12. PubMed ID: 9127315
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 44.